Pilot Minimal Residual Disease in CLL (Not Accredited)

 

The measurement of minimal residual disease (MRD) populations is often performed following treatment for leukaemic disorders. The levels of MRD are used as a predictive factor for relapse and as an indicator for patients entering remission. As such the measurement of MRD can have a direct effect on the treatment regimen of a patient.

 

This programme issues stabilised whole blood with laboratories required to determine the level of minimal residual disease by flow cytometry, please note this programme is not suitable for the measurement of MRD by molecular methods.

 

Each send out includes two follow up samples of a known CLL case post treatment at different time points. Participants will be asked to quantify the level of residual disease in these samples

 

Two samples are issued per trial and this programme issues samples a minimum of 2 times per annum and a maximum of 4.

 

No activities in relation to this EQA programme are subcontracted.

 

Example Minimal Residual Disease in CLL Report
To view the annotations on this report, please download the PDF and view in a PDF reader such as Adobe Acrobat.
MRD CLL annotated.pdf
Adobe Acrobat document [609.3 KB]
Print Print | Sitemap

Follow Us Online!
Facebook Twitter LinkedIn Youtube

Disclaimer

Last updated 24th May 2017 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information, please click here.